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A B S T R A C T
Infections caused by Pseudomonas aeruginosa become increasingly difficult to treat because these bacteria have
acquired various mechanisms for antibiotic resistance, which creates the need for mechanistically novel anti-
biotics. Such antibiotics might be developed by targeting enzymes involved in the iron uptake mechanism be-
cause iron is essential for bacterial survival. For P. aeruginosa, pyoverdine has been described as an important
virulence factor that plays a key role in iron uptake. Therefore, inhibition of enzymes involved in the pyoverdine
synthesis, such as PvdP tyrosinase, can open a new window for the treatment of P. aeruginosa infections.
Previously, we reported phenylthiourea as the first allosteric inhibitor of PvdP tyrosinase with high micromolar
potency. In this report, we explored structure-activity relationships (SAR) for PvdP tyrosinase inhibition by
phenylthiourea derivatives. This enables identification of a phenylthiourea derivative (3c) with a potency in the
submicromolar range (IC50 = 0.57 + 0.05 µM). Binding could be rationalized by molecular docking simulation
and 3c was proved to inhibit the bacterial pyoverdine production and bacterial growth in P. aeruginosa PA01
cultures.
Pseudomonas aeruginosa is a Gram-negative pathogen that causes
infection in many organs. Although these bacteria barely infect healthy
individuals, cystic fibrosis patients and immunocompromised in-
dividuals suffer from high morbidity and mortality in P. aeruginosa in-
fections.1 However, the development of antibiotic resistance increas-
ingly limits the treatment options for P. aeruginosa infections.2 P.
aeruginosa employs intrinsic, acquired and adaptive mechanisms to
counter most antibiotics including aminoglycosides, quinolones, and β-
lactams. Expulsion of antibiotic molecules by efflux pumps is one of the
examples of the intrinsic and adaptive mechanisms. The acquired re-
sistance mechanisms can be obtained through either horizontal transfer
of resistance genes or mutational changes. Biofilm formation is one of
the examples of adaptive antibiotic resistance.3 In 2017, the World
Health Organization (WHO) has classified carbapenem-resistant P.
aeruginosa into category 1, which is a category of the most urgent need
for developing new antibiotics to treat the infection.4
Bacterial transport mechanisms to acquire iron provide attractive
targets to develop new antibiotics since iron is an essential element that
acts as a cofactor in many biological reactions in bacteria including P.
aeruginosa.5 Moreover, the low availability of iron in the human body is
one of the growth-limiting factors for P. aeruginosa. Since iron III (Fe3+)
is hardly soluble and cannot passively diffuse into the bacterial cells,
these bacteria secrete siderophore pyoverdine, an iron III (Fe3+) che-
lating molecule, to transport iron into the cell via the FpvA transporter.6
Pyoverdine biosynthetic enzymes have been proposed as novel anti-
biotic targets because small molecule inhibitors would downregulate
the production of pyoverdine resulting in limited iron acquisition. In
support of this concept, several studies have reported that P. aeruginosa
pyoverdine-deficient mutants have reduced virulence in animal and
plant infection models.7,8 Therefore, small molecule inhibitors that in-
terfere with the pyoverdine biosynthetic enzymes have potency for the
development of new treatments for P. aeruginosa infections.
In a low iron condition, the biosynthesis of pyoverdine is induced.
Initially, in the absence of complex Fe-ferri uptake regulator (FUR)
which otherwise binds to the PvdS promoter, to block the production of
the extracytoplasmic function (ECF)-sigma factor PvdS. After transla-
tion, PvdS binds to the IS boxes of PVDI genes, starting the transcription
and translation of PVDI proteins. The non-ribosomal peptide
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synthetases (PvdL, PvdI, PvdJ, and PvdD) together with MbtH, PvdG,
PvdH, PvdA and PvdF assemble the precursor siderophore PvdIq in the
cytoplasm. Subsequently, PvdE transports PvdIq to the periplasm then
it is cleaved by PvdQ to form ferribactin and myristoleic acid. The
conversion of ferribactin to pyoverdine involves at least four different
enzymes: PvdM, PvdN, PvdO, and PvdP at the final step of the bio-
synthesis.9,10 PvdP is a tyrosinase known from its role for the matura-
tion of pyoverdine chromophore.11 Even though, tyrosinases are found
in almost every organism: human, animal, plant, mushroom, and bac-
teria, the PvdP enzyme is different compared to other tyrosinases. The
closest homolog is a tyrosinase of Bacillus megaterium (PDB ID = 3NQ5)
sharing sequence identity 30,7% (Clustal Omega, http://www.ebi.ac.
uk/Tools). Moreover, PvdP also has a unique homodimer structure
where each monomer consists of 2 different domains i.e.: beta-barrel
domain (BBD) and tyrosinase domain (TYD) are not found in the other
tyrosinase structure based on the recent reports. As in other tyrosinases,
its active site is formed by a di-copper center of six histidine residues,12
but in the case of PvdP, this is uniquely covered by a C-terminal lid in
the apo state.13
In line with the facts above, we have reported that most of the
tyrosinase inhibitors, for example, mushroom tyrosinase inhibitors do
not inhibit PvdP tyrosinase activity. Surprisingly, phenylthiourea (PTU)
was found to inhibit PvdP tyrosinase activity at micromolar con-
centration. Moreover, a crystal structure demonstrated the binding of
PTU to an allosteric binding site instead of the tyrosinase active site.13
This provides opportunities to develop inhibitors that target the allos-
teric binding site, which seems to be confined to fluorescent pseudo-
monads. Therefore, identifying PvdP tyrosinase inhibitors that selec-
tively interfere with the allosteric binding site, might result in a specific
antibiotic with limited side effects as it does not bind to other tyr-
osinases.
To obtain sub-micromolar inhibitors, we designed and synthesized a
series of PTU derivatives. Some of the generated derivatives show in-
hibition at the low micromolar range. Kinetic studies were performed to
determine the type of inhibition and, with molecular docking revealing
the binding of the compound at the allosteric binding site, the high
affinity was being explained.
Design and synthesis of PTU derivatives
In our previous study, PTU was discovered as an allosteric inhibitor
that binds at the interface of the beta-barrel domain (BBD) and C-
terminal domain (TYD) of PvdP and thereby inhibits the tyrosinase
enzymatic activity.13 A focused compound collection of PTU derivatives
was synthesized to improve the PvdP tyrosinase inhibitory potency and
to explore structure–activity relationships. The desired PTU derivatives
were generated by the synthesis of the required phenylthiocyanates that
were reacted with the corresponding amines to provide the desired
phenylisothiocyanates as final products (Scheme 1). The phenyli-
sothiocyanates were prepared through a one-pot procedure, in which
the phenylamines and carbon disulfide were reacted to provide the
dithiocarbamate that was desulfurized with sodium persulfate to give
the products in good yields after filtration and wash with water.14 The
phenylisothiocyanates were applied without prior purification for
coupling with the corresponding amines to generate the disubstituted
thioureas (Table 1). The compounds were subjected to filtration to
obtain the pure products as white precipitates, except for 1b and 3b for
which flash column purification was needed. The final product was
obtained in variable but sufficient yields (38–99%) over two steps.
Phenylurea (1a) was synthesized as an equivalent of phenylthiourea by
charging aniline with potassium cyanate in an aqueous 10% AcOH
solution. The product 1a was formed and isolated by extraction and
recrystallization to provide 1a in a yield of 98%.15
Structure-activity relationship of PTU derivatives
The structure-activity relationships for PvdP tyrosinase inhibition
by the 14 membered compound collection were investigated. First,
modification of the thiourea functionality of phenylthiourea provided
phenylurea 1a, which provided less than 50% inhibition of PvdP tyr-
osinase activity at a concentration up to 100 μM. The crystal structure
of PvdP bound to PTU (PDB ID = 6RRP) showed the thioketone group
interacting with Trp320 and Ser329. The substitution of this group with
a ketone group breaks the interaction between the compound and those
residues resulting in the loss of its inhibitory activity on PvdP. This
means the thio ketone group is important for the inhibitory activity of
PTU on the tyrosinase activity of PvdP.
Next, the substitution of the thiourea functionality of PTU was ex-
plored (Table 1) and it was found that methyl (1b), vinyl (2b) or phenyl
(3b) substitution decreased the potency. In contrast, ethyl phenyl or
benzyl substitution of phenylthiourea improved the inhibitory potency
by a factor 10 or more. Structural variation of the benzyl substitution
provided compound 3c with a more than 100-fold improved potency
compared to non-substituted PTU with an IC50 of 0.57 μM. Other sub-
stitution patterns, such as 2-Cl, 2,6-Cl, 4-F, 4-H, 4-Br or 4-OCH3, pro-
vided IC50 between 7.6 and 23.5 μM. Further substitutions of the phenyl
ring of PTU were investigated based on 3c as a starting point. However,
1d and 2d with a 4-methyl or 4-dimethylamino provided IC50 values
that indicated reduced potency compared to 3c.
Kinetic study and inhibition activity on PvdP-trunc
To establish the mechanism of PvdP tyrosinase inhibition,
Michaelis–Menten enzyme kinetics analysis in the presence of inhibitor
3c was performed. The Lineweaver–Burk double reciprocal plot shows
that inhibitor 3c causes a decrease in the Vmax values, whereas the Km
values remain constant (Table 2), indicating a non-competitive inhibi-
tion. These results are in line with the data obtained previously for PTU
for which we also reported non-competitive inhibition. Obviously, the
substitution on the thiourea functionality of PTU with 4-chlorobenzyl
improved the inhibition activity but did not change the mechanism of
inhibition. Previously, we described that PTU mediated inhibition of
PvdP tyrosinase activity involves a C-terminal lid rearrangement and
the absence of this lid precludes PTU mediated inhibition of PvdP tyr-
osinase activity. Inhibitor 3c was tested for inhibition of wild-type PvdP
in comparison to a PvdP variant that is truncated for the C-terminal lid.
Similar to the parent compound, this PTU derivative lost its potent
inhibition activity on the truncated enzyme, which indicates that in-
hibitor 3c has the same mechanism of inhibition as described for PTU
that stabilizes the C-terminal lid covering the active site (Fig. 1D).
Mushroom tyrosinase inhibition
In a follow-up experiment, three most potent of the PTU derivatives
were tested on mushroom tyrosinase to investigate their effect on other
tyrosinases. The IC50 values of the compounds increased dramatically,
the IC50 of 1c and 2c were greater than 500 µM and the IC50 of the most
potent compound (3c) increased up to 328 ± 27 µM, an increase of
more than 500 times compared to PvdP (Table 3). It means that the
derivatives of PTU are not only non-competitive inhibitors, but also
very specific inhibitors for PvdP.
As reported, PTU is a competitive inhibitor of mushroom tyr-
osinase16 and it binds at the active site of tyrosinase.17 Knowing that
the inhibition of the new derivatives on mushroom tyrosinase is lost,
this suggests that its ability to act as a competitive inhibitor is gone.
This is most likely attributed to the change in the size and shape of the
molecule. The addition of a chlorinated phenyl ring has increased the
size of the molecule in such a way that it does not fit into the active site
J.P. Wibowo, et al. Bioorganic & Medicinal Chemistry Letters 30 (2020) 127409
2
anymore. In conclusion, the PTU derivatives are specific to PvdP due to
the nature of their inhibition and their size which prevents them from
competitively inhibiting other tyrosinases such as mushroom tyr-
osinase. This implies that the compounds do also not cross-react with
human tyrosinases, which makes them interesting candidates for anti-
biotics.
Scheme 1. Synthesis of PTU derivatives. Reagents and conditions: i. KNCO, AcOH, water, r.t., overnight, 90%; ii. 1) K2CO3, CS2, water, r.t., overnight; 2) Na2S2O8,
K2CO3, water, r.t., 1 h, 99%; iii. R2NH2, EtOH, r.t., 4 h, 45–97%.
Table 1
Structure and activity of PTU derivatives against PvdP.
Structure Compound R IC50 (µM)a





4b 22.6 ± 2.6
1c 2-Cl 7.9 ± 0.5
2c 2,6-Cl 7.6 ± 0.8
3c 4-Cl 0.57 ± 0.05
4c 4-F 13.6 ± 3.4
5c H 19.4 ± 2.5
6c 4-Br 23.5 ± 3.1
7c 4-OCH3 19.3 ± 2.5
1d 4- CH3 22.3 ± 3.3
2d 4- N(CH3)2 14.3 ± 3.7
N.I. = no inhibition.
a = averages derived from three experiments + SD (standard deviation).
Table 2
The kinetic parameters of PvdP tyrosinase activity in the presence of a various
concentration of compound 3c.
Compound Concentration (µM) Vmax (A475/min) Km (mM)
3c 0 0.0155 1.136
0.2 0.0126 1.131
0.5 0.0111 1.136
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Molecular docking analysis
In order to link the observed SAR to binding information, 3c was
docked at the allosteric binding site of the PvdP enzyme in a similar
fashion as with the previously identified non-competitive inhibitor. The
docking result showed 3c provided a binding configuration similar to
PTU (Fig. 2A), in which the thioketon moiety forms hydrogen bonds
with Trp320 and Ser329. The 4-chlorobenzyl group extended into the
available binding site and extra interactions were formed with sur-
rounding residues. The benzyl ring interacts with Asp56 and Ala319
and the chlorine group interacts with Arg57 (Fig. 2B).
Fig. 1. Inhibition activity of 3c on PvdP tyrosinase activity. (A) IC50 graph of 3c, (B) Michaelis-Menten graph of 3c, (C) Lineweaver-Burk plots of 3c; ● = 0, ■ = 0.2,
▲ = 0.5 µM of compound 3c, (D) effect of 3c on PvdP WT (wild type) and PvdP-trunc, an asterisk (*) indicates a significant and n.s. indicates a non-significant
difference between treatments (P < 0.05, Student t test). Data were presented as mean + SD.
Table 3
Inhibitory activity of the potent compounds on PvdP and mushroom tyrosinase.
Compound IC50 + SD (µM)
PvdP Mushroom tyrosinase
1c 7.9 + 0.5 N.I.
2c 7.6 + 0.8 N.I.
3c 0.57 + 0.05 328 + 27
SD = standard deviation, N.I. = no inhibition.
Fig. 2. Result of docking study of 3c on PvdP. (A) Superimposition of docking result (yellow) and crystal structure of PvdP bound to PTU (PDB ID = 6RRP, magenta),
(B) interactions between 3c and the residues of PvdP.
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Based on the docking result above, it is concluded that substitution
with the chlorobenzyl group in the para position gave extra interaction
of the compound to PvdP. As reported in our previous study, PTU in-
hibits the enzymatic activity of PvdP due to the re-arrangement of the
C-terminal lid covering the active site.13 Apparently, these extra in-
teractions provided more anchor points on PvdP resulting in a more
stable re-arrangement of the lid. In consequence, compound 3c has a
stronger effect on PvdP than the parent compound.
Inhibition of pyoverdine production
To investigate the inhibition of pyoverdine synthesis by the com-
pound, we tested compound 3c against living cells of P. aeruginosa
PA01 for 24 h in a low iron medium. In an iron-depleted condition, the
bacteria will start to produce pyoverdine as an iron transporter. A serial
dilution of compound 3c (200 – 0.79 µM, final concentration in DMSO
1%) was prepared and mixed with the bacterial culture in a low iron
medium. DMSO 1% was used as a negative control. After 24 h in-
cubation, we measured the production of pyoverdine at 405 nm and the
cell-growth at 600 nm. The results showed a dose-dependent inhibitory
activity of 3c on the production of pyoverdine. The production of
pyoverdine was inhibited by 3c with an IC50 value of 44.9 ± 5.9 µM
(Fig. 3) after being normalized with the cell-growth. The effect ob-
served on bacterial cell assay is in line with the inhibition of PvdP
tyrosinase activity. There is however a concentration difference of al-
most two orders of magnitude between the in vivo and the in vitro tests.
These differences might be caused by a limited ability of the compound
to reach the site of action, i.e. the periplasm. A similar difference be-
tween in vitro activity and inhibition inside the periplasm is seen more
often.18,19 This might be improved in the future by optimizing the water
solubility, the log P and other physical–chemical properties important
for the compound to pass the outer membrane of P. aeruginosa.
Several studies have reported targeting pyoverdine production to
develop antivirulence agents of P. aeruginosa.18–21 A recent study re-
ported that some pyoverdine inhibitors reduce the pathogenicity of P.
aeruginosa and improve the survival of Caenorhabditis elegans infection
model.22 Our report provided a new alternative to develop anti-
virulence against P. aeruginosa.
In this study, the structure–activity relationships of PTU derivatives
against PvdP enzymatic activity were investigated. Several compounds
showed low micromolar potency against PvdP tyrosinase activity.
Remarkably, the most potent compound 3c exhibited a strong inhibi-
tion against PvdP with an IC50 of 0.57 ± 0.05 µM. 3c was confirmed to
be an allosteric inhibitor similar to PTU, but with much higher potency.
Binding modes of 3c with PvdP were studied by molecular docking
simulation and found to be consistent with PTU binding mode. In ad-
dition, 3c was active in a bacterial cell assay in inhibiting the produc-
tion of pyoverdine and bacteria cell growth with an
IC50 = 44.9 ± 5.9 µM. The discovery and development of PTU
derivative as an allosteric inhibitor against the production of iron
chelators to suppress bacterial growth could be an effective strategy to
treat infections and also to solve the issue of antibiotics resistance.
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